- One time offer
- $175
- Subscription
- $165/month advertised
- Preparation
- Route and quantity require confirmation
- Public NAD report
- Marked upload pending when checked
What this provider actually advertises
BRAVO1 Wellness presents NAD+ within a broader catalog of wellness protocols. Its dedicated page offers a physician-review pathway, a $175 one-time choice and a $165 monthly subscription. Those prices identify the commercial entry points. They do not establish that every reader will receive the same preparation, route or quantity after the medical assessment.
That distinction matters because the page discusses several possible ways to administer NAD+ without identifying a universal finished product for the listed offer. We review the provider and its NAD+ plan separately, keeping the plan in a clinician-selected category. We have not enrolled, obtained a prescription or verified which formulation would be supplied to an individual.
A subscription saving with an incomplete denominator
The monthly headline is $10 below the one-time price. That arithmetic is straightforward, but the comparison remains incomplete until the contents and supply period are known. A one-time order might not represent the same length of care as a subscription payment. Ask for the amount charged now and the exact item or service attached to it.
The written quote should distinguish medical review, medication, supplies, shipping and follow-up. It should also explain the next renewal and the deadline for stopping another shipment. A general statement about fulfillment after physician approval describes a shipping process; it does not establish how quickly approval occurs or how quickly a clinical question receives an answer.
Testing claims need documents that can be inspected
BRAVO1 describes independent testing and batch traceability. The public laboratory library reviewed for this article nevertheless marked the NAD+ documentation as upload pending. A promise to provide a certificate and an accessible certificate for the proposed batch are different forms of evidence. We did not inspect a completed NAD+ batch report through that library.
Before treating the testing language as verified product assurance, request the actual report and match its batch identifier to the dispensed preparation. Ask what the report measures, who performed the testing and whether its scope is relevant to the selected route. A purity statement alone would not establish every quality attribute of a sterile finished preparation.
How to make the clinical and purchase decisions
The provider's wellness discussion connects NAD+ with cellular energy and aging. Biological mechanisms do not establish predictable improvements from the proposed plan. Ask which evidence concerns the actual formulation and purpose, and whether any available findings are ingredient research, observations from customers or controlled studies of a comparable finished product.
If a compounded medication is proposed, its FDA status should be explained separately from the provider's pharmacy and physician claims. Compounded drugs are not FDA-approved. The useful next step is a specific prescription proposal and itemized price, accompanied by accessible quality information. BRAVO1 belongs in this register as a documented offer with important unresolved details, rather than as a verified clinical or lowest-price leader.
Useful distinctions
- One-time and monthly options shown
- A physician-review process is described
- Public laboratory library identifies document availability
Limitations to weigh
- A single dispensed formulation is not established
- Accessible NAD batch report was pending
- Price inclusions and renewal conditions need confirmation
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.